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Abstract: In order study methotrexate nephrotoxicity, the activities of proximal tubule 
epithelial cell membrane enzymes: alkaline phosphatase (AP) and lactate dehydrogenase 
(LDH) were determined in 12-h-urine samples of 30 patients with lymphoblastomous 
leukemia. The patients were i.v. receiving 4 individual methotrexate doses of 2000 mg/m2 
every 15 days followed by leucovorin as a protector. Control and methotrexate-treated group, 
each consisting of 30 examinees, included 4-10 years old children of both sexes. 
 Statistically significant increase of AP and LDH activities, expressed as unuts/mmol 
creatinine was observed after the second therapy (p < 0.05) in relation to the control. Based on 
these results it can concluded that nephrotoxic methotrexate action is ireversible during the 
time period after the second applications at the level of proximal tubule epithelal cell. 
Keywords: methotrxate, nephrotoxicity, urine, alkaline phosphaatase, lactate-
dehydrogenase. 
 
 
 
1. INTRODUCTION 
 
Methotrexate is a folate synthesis inhibitor 
and one of the first and most commonly applied 
medicaments in carcinoma chemotherapy. It is 
efficient against osteosarcoma and breast, head and 
lung tumor [1−5]. Methotrexate is applied in high, 
medium and low doses most frequently 
intravenously [6]. High doses of 500 or more mg/m2 
are applied in cases of leukemia, lymphoma, 
leptomeningeal metastases and osteosarcoma. 
Medium methotrexate doses from 50 to 500 mg/m2 
are applied in cases of gestational trophoblastic 
diseases, while the low doses of 50 or less mg/m2 are 
administered in anti-inflammatory therapy of 
rheumatoid arthritis and psoriasis [7−8]. 
Intravenous doses methotrexate doses higher 
than 1000 g/m frequently cause a series of system 
toxicities. Besides skin, mucosa, liver and brain, 
they affect the kidney tissue too [9]. In kidney tissue 
methotrexate can cause glomerular and tubular 
toxicity, however the clinical trials show that this is 
not a general occurrence [10]. Low methotrexate 
doses already deteriorate the existing glomerular and 
tubular cell necrosis. The risk of occurrence of 
nephrotoxicity of methotrexate can be increased by 
genetic polymorphism included in folate metabolism 
[11]. 
In previous trials nephrotoxicity of 
methotrexate was most frequently determined for 
applications of low doses of drug for anti-
inflammatory treatment of rheumatoid arthritis and 
psoriasis. Glomerular function was monitored by 
determining the clearance of inuline, creatinine, 
ethylene diamine tetra acetate (EDTA) and by 
increasing the concentration of albumin in urine 
[12−13]. Tubular function was monitored by 
determining the concentration of electrolyte in 
blood, 1-or 2-microglobuline in urine and tubular 
enzymuria [14−15]. 
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The purpose of this paper was to determine, 
on a representative number of subjects suffering 
from lymphoblastic leukemia and treated with high 
methotrexate doses, possible nephrotoxicity by 
monitoring enzymuria of tubular alkali phosphatase 
enzymes, AP (EC. 3.1.3.1) and lactate-
dehydrogenase, LDH (EC. 1.1.1.27.). 
 
 
2. MATERIAL AND METHODS 
 
60 children of age from 4 to 10 years were 
included in the study. The children were the patients 
of the Clinic for Children Diseases of University-
Clinical Centre in Banja Luka. The experimental 
group comprised 30 subjects with acute lymphoblast 
leukemia and they were treated intravenously with 
individual methotrexate doses of 2000 mg/ m2. 
Methotrexate was applied in 4 individual doses at 
15-day interval and with leucovorin rescue which 
was applied in doses of 15 mg/m2 at 42, 48 and 54 
hours after administration of methotrexate. In 
control group there were 30 subjects who did not 
have lymphoblast leukemia or any kidney or urinary 
tract-related disease.  
The morning 12-hour urine was taken from 
the subjects in triplets, 24 hours before and 24 hours 
after each individual therapy of the experimental 
group subjects and was kept at -25о C until analysis. 
The data on the age, sex, height, body mass and 
health condition of the subjects were collected based 
on the questionnaire during the first taking of urine.  
Before urine analysis enzymes were separated 
by gel filtration [16]. Activities of enzymes AP [17] 
and LDH [18] and the creatinine concentrations 
were determined by spectrophotometry. Enzyme 
activity was expressed in international units of 
enzyme activity by mmol/l. The results were 
analyzed using standard statistical methods, 
expressed as mean values ± standard deviation and 
graphically presented. Significance of the 
differences between the results obtained for 
experimental and control group was determined by 
Student’s t-test. 
 
  
3. RESULTS 
 
The mean results of AP and LDH enzyme 
activities with standard deviations were presented in 
figures 1 and 2. As shown in Figure 1, statistically 
significant increase of activity of AP in urine of 
subjects treated with methotrexate compared to 
control group subjects occurred after the second 
therapy. The mean values of enzyme activity with 
standard deviations after the second therapy 
amounted to x  = 2,22 ± 0,6 for the experimental 
group compared to x = 1,48 ± 0,45 for the control 
group (p < 0,05). Statistical significance of 
differences in the activities of experimental 
compared to the control group was kept even after 
two remaining therapies.  
 
 
 
 
Figure 1. Kinetics of activity changes of alkaline phosphatase (AP) in urine of the patients treated with 4 therapy doses 
of methotrexate and of appropriate control values expressed as mean values ± S.D 
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Figure 2. Kinetics of changes of the activity of lactate-dehydrogenase (LDH) in urine of the patients treated 
with 4 therapy doses of methotrexate and appropriate control values expressed as mean values ± S.D 
 
 
The mean values of LDH enzyme activity for 
the experimental group, the first time after the 
second therapy, significantly increased too, first time 
after the second therapy, compared to the control 
group when they amounted to x  = 4,48 ± 1,61 /as 
opposed to x  = 3,72 ± 1,22 (p < 0,05). The level of 
differences of statistical significance for LDH was 
kept all the time until the end of the therapy. 
 
 
4. DISCUSSION 
 
Nephrotoxic activity of methotrexate, 
administered intravenously to patients of 4 to 10 
years of age, was observed in our study. The patients 
suffered from lymphoblast leukemia. Nephrotoxicity 
was determined by monitoring enzymuria of two 
enzymes of proximal tubule, alkaline phosphatase 
(AP) and lactate-dehydrogenase (LDH). A 
statistically significant increase of the activity of 
both enzymes was registered after the second 
therapy (Figures 1 and 2) with statistical significance 
of 0.05. The obtained values of enzyme activities of 
AP and LDH are not in conformity with the results 
obtained by Miedany et al. [20] and Minaur et al. 
[21] most probably because they observed 
enzymuria while applying the therapy of low dose 
methotrexate. The obtained results are in conformity 
with the results of Westhuyzen-a сар. trial [22]. 
Their conditions of conducting the trial were similar 
to ours.  
As AP is a lysosomal enzyme, and LDH 
cytosolic enzyme, an increase in their activity after 
implementing the second therapy means that 
nephrotoxicity occurred due to changes within 
proximal tubule epithelium cells, at the level of 
organelle, lysosome and cytostol. After statistically 
significant increase of the activity of both enzymes 
after implemented second therapy and before the 
beginning of the third, i.e. of the fourth therapy, 
enzyme activities were not normalized. This points 
out at a conclusion that the nephrotoxic effect of 
high methotrexate doses is cumulative and that it is 
accompanied by irreversible changes within the cells 
of affected tissue resulting in cell apoptosis and 
necrosis of proximal tubule epithelium necrosis.  
 
 
 5. CONCLUSION 
 
Nephrotoxic activity of methotrexate applied 
to the patients in high doses in four therapies at 15-
day interval and with leucovorin rescue was 
confirmed in this trial. Nephrotoxicity was 
determined by significant increase of enzymes AP 
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and LDH activity in urine. Nephrotoxic activity of 
methotrexate is cumulative and the damage occurs at 
the level of cell organelles. Administration of high 
methotrexate doses over a long period of time results 
in the necrosis of proximal tubule epithelium tissue. 
Therefore, whenever possible, high doses of 
methotrexate in therapy should be avoided.  
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 
 
АКТИВНОСТИ ЕНЗИМА АЛКАЛНЕ ФОСФАТАЗЕ И ЛАКТАТ- ДЕХИДРОГЕНАЗЕ  
У УРИНУ ПАЦИЈЕНАТА ТРЕТИРАНИХ МЕТОТРЕКСАТОМ  
 
Сажетак: Ради утврђивања нефротоксичности метотрексата, одређиване су 
активности ензима проксималних тубула, алкалне фосфатазе (АП) и лактат- 
-дехидрогеназе (ЛДХ) у 12-часовном урину 30 пацијената који су били обољели од 
лимфобластне леукемије. Њима је интравенски аплициран метотрексат у четири 
појединачне дозе од 2 000 мг/м2 са размаком од 15 дана и уз заштиту са 
леуковорином. Иста одређивања су вршена и у 12-часовном урину 30 испитаника 
контролне групе. Обје групе су се састојале од испитаника оба пола, старости од 
четири до десет година.  
Статистички значајна повећања активности АП и ЛДХ, изражених у 
интернационалним јединицама ензимске активности по милимоловима креатинина, 
експерименталне у односу на контролну групу, регистрована су након прве двије 
терапије (p < 0,05) и повећања са истом статистичком значајношћу су задржана све 
до краја терапије. На основу добијених резултата се може закључити да је 
нефротоксично дјеловање метотрексата изражено, да је на нивоу ћелија епитела 
проксималних тубула и да је кумулативно. 
Кључне ријечи: метотрексат, нефротоксичност, алкална фосфатаза, лактат- 
-дехидрогеназа. 
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